Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorLÉONARD, Cédric
dc.contributor.authorTATON, Benjamin
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorLAZARO, Estibaliz
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorMERVILLE, Pierre
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorVIALLARD, Jean-François
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorCOUZI, Lionel
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorRIVIÈRE, Etienne
dc.date.accessioned2025-05-05T10:29:50Z
dc.date.available2025-05-05T10:29:50Z
dc.date.issued2025-01-01
dc.identifier.issn1664-3224en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206546
dc.description.abstractEnCytopenias occur frequently after kidney transplantation but posttransplantation thrombocytopenia (PTTCP) frequency has rarely been reported. This monocenter, retrospective study aimed to describe PTTCP frequency, causes, treatments and outcomes. PTTCP was defined as thrombocytopenia with ≥2 platelet counts <100×10/L after first month posttransplantation. Among 2118 kidney-transplant recipients between 2002 and 2018, 189 (8.9%) developed PTTCP. Their mean platelet-count nadir was 51×10/L [range 4-96×10]; nadir was <50×10/L for 87 (46.0%) patients. Main identified PTTCP etiologies were drugs (24.3%), or infectious diseases (20.1%; cytomegalovirus causing 79.4% of them), or unknown for 26 (13.7%). Bleeding rate was high (32.7%), with 40 (64.5%) severe episodes. During follow-up, 103 (54.5%) patients suffered graft loss or died at a median of 5.41 years post-PTTCP episode. Multivariate analyses retained a severe bleeding episode as being significantly associated with antiplatelet or anticoagulation therapy and pancytopenia, and age, creatininemia, transplantation-to-PTTCP interval and severe bleeding as significant risk factors for death or graft loss. PTTCP is frequently associated with severe bleeding, which is a risk factor for graft loss and death. Those findings suggest that the risk/benefit ratio of antiplatelet or anticoagulation therapies should be systemically evaluated for PTTCP patients.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enHumans
dc.subject.enKidney Transplantation
dc.subject.enMale
dc.subject.enThrombocytopenia
dc.subject.enFemale
dc.subject.enMiddle Aged
dc.subject.enRetrospective Studies
dc.subject.enAged
dc.subject.enAdult
dc.subject.enRisk Factors
dc.subject.enPlatelet Count
dc.subject.enPostoperative Complications
dc.subject.enHemorrhage
dc.title.enThrombocytopenia following kidney transplantation: a frequent, underestimated and potentially severe complication.
dc.title.alternativeFront Immunolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fimmu.2025.1519256en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed40098949en_US
bordeaux.journalFrontiers in Immunologyen_US
bordeaux.page1519256en_US
bordeaux.volume16en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-05056039
hal.version1
hal.date.transferred2025-05-05T10:29:58Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Frontiers%20in%20Immunology&amp;rft.date=2025-01-01&amp;rft.volume=16&amp;rft.spage=1519256&amp;rft.epage=1519256&amp;rft.eissn=1664-3224&amp;rft.issn=1664-3224&amp;rft.au=L%C3%89ONARD,%20C%C3%A9dric&amp;TATON,%20Benjamin&amp;LAZARO,%20Estibaliz&amp;MERVILLE,%20Pierre&amp;VIALLARD,%20Jean-Fran%C3%A7ois&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée